Company description

CASI Pharmaceuticals, Inc. (ticker CASI) is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics for patients with cancer and other serious diseases. Founded in 1991, CASI has a strong track record of clinical achievements and a robust pipeline of potential drug candidates. The company's main focus is on developing products for the treatment of hematological malignancies and other cancers, as well as for autoimmune and inflammatory diseases. CASI's innovative approach to drug development is centered around collaborations with renowned research institutions and strategic partnerships with leading pharmaceutical companies. With a global presence, CASI is committed to improving the lives of patients worldwide through the discovery, development, and commercialization of valuable new drugs. Their dedication to scientific excellence and commitment to patient care has made them a leader in the biopharmaceutical industry. As they continue to advance their promising portfolio of therapies, CASI remains poised for continued success and growth.